Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.

Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.
Br J Dermatol. 2019 Nov 01;:
Authors: Del Regno L, Louveau B, Battistella M, Sadoux A, Baroudjian B, Delyon J, Serror K, Allayous C, Lebbe C, Mourah S, Jouenne F
Abstract
Innovative therapeutic strategies in metastatic melanoma depend on molecular features and the combination of BRAF and MEK inhibitors (BRAFi+MEKi) which has recently shown an improved clinical efficacy in BRAFV600MUT metastatic melanoma patients, is now the standard of care. BRAF and NRAS activating mutations lead to the MAPK pathway deregulation1 and may coexist despite their earlier description as mutually exclusive2 . This event is probably related to the existence of several mutually-exclusive subclones corresponding to a mixture of singly-mutated melanoma cells or may have arisen as shown by in vitro treatment3 . A study of 3399 melanomas highlighted BRAFV600E /RAS mutations co-occurrence in 1.5% of primary tumours and 5.6% of metastatic lesions4 .
PMID: 31675434 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - October 31, 2019 Category: Dermatology Authors: Del Regno L, Louveau B, Battistella M, Sadoux A, Baroudjian B, Delyon J, Serror K, Allayous C, Lebbe C, Mourah S, Jouenne F Tags: Br J Dermatol Source Type: research